General Information of the Compound
Compound ID |
CP0002393
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Show/Hide
|
||||||||||||||||||
Synonyms |
Xeljanz (TN)
1-Piperi
1259404-17-5
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile
477600-75-2
87LA6FU830
CHEBI:71200
CHEMBL221959
CP 690550
CP-690,550
CP-690550
Tasocitinib
Tofacitinib
Tofacitinib (CP-690550,Tasocitinib)
UNII-87LA6FU830
racemic-tofacitinib
tofacitinibum
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C16H20N6O
|
||||||||||||||||||
Molecular Weight |
312.377
|
||||||||||||||||||
Canonical SMILES |
C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
Show/Hide
|
||||||||||||||||||
InChIKey |
UJLAWZDWDVHWOW-YPMHNXCESA-N
|
||||||||||||||||||
CAS |
477600-75-2
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01540, Non-receptor tyrosine-protein kinase TYK2
Cell-based Assay
Biochemical Assays
Protein ID: PT01659, Tyrosine-protein kinase JAK1
Cell-based Assay
Biochemical Assays
Protein ID: PT01214, Tyrosine-protein kinase JAK2
Cell-based Assay
Biochemical Assays
Protein ID: PT00892, Tyrosine-protein kinase JAK3
Cell-based Assay
Biochemical Assays
Protein ID: PT05132, Tyrosine-protein kinase JAK3
Cell Viability or Cytotoxicity Assay
Cell Line ID | Cell Line Name | Cell Line Organism | |
CL000227 | HFF | Homo sapiens (Human) | 1 |
1 |
IC50 > 10000 nM
|
TI
LI
LO
TS
|
---|
Clinical Information about the Compound
Drug 1 ( Tofacitinib )
Drug Name | Tofacitinib | ||
---|---|---|---|
Company | Pfizer | ||
Indication | |||
Target(s) |